Medicenna Therapeutics Corp.
MDNAF- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001807983
No open-market purchases or sales by Medicenna Therapeutics Corp. insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
Q2 2021 vs. Q1 2021
How the institutions holding Medicenna Therapeutics Corp. changed between Q1 2021 and Q2 2021.
All holders in Q2 2021All holders in Q1 2021
| Measure | Q1 2021 | Q2 2021 | Change |
|---|---|---|---|
| Holders | 31 | 26 | −5 |
| Shares | 5.53M | 5.02M | −515.4K (−9.3%) |
| Value | $22.9M | $15.4M | −$7.49M (−32.7%) |
New holders (4)
Institutions that held Medicenna Therapeutics Corp. at the end of Q2 2021 but not at the end of Q1 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| ACT Capital Management, LLC | 350,000 | $1.05M | 0.54% |
| Davenport & Co LLC | 25,150 | $76.0K | 0.00% |
| Citadel Advisors LLC | 24,203 | $73.0K | 0.00% |
| Bank of America Corp | 19 | $0 | 0.00% |
Sold out (9)
Institutions that held Medicenna Therapeutics Corp. at the end of Q1 2021 and filed for Q2 2021 without it.
| Institution | Shares, Q1 2021 | Value, Q1 2021 |
|---|---|---|
| Janus Henderson Group PLC | 529,325 | $2.15M |
| Millennium Management LLC | 122,488 | $500.0K |
| Marshall Wace, LLP | 80,401 | $328.0K |
| Creative Planning | 39,000 | $159.0K |
| Goldman Sachs Group Inc | 36,902 | $151.0K |
| Susquehanna International Group, LLP | 27,823 | $114.0K |
| Marshall Wace North America L.P. | 19,300 | $79.0K |
| BlackRock Inc. | 5,775 | $24.0K |
| Toronto Dominion Bank | 111 | $0 |